Topiramate exposure in early pregnancy is linked to higher rates of major malformations and more specifically to increased risk of oral clefts, with risk rising at higher doses.
In this large cohort study analyzing data from publicly insured Medicaid beneficiaries, the overall risk of malformations was lower with buprenorphine than with methadone.
Multiple studies have associated first trimester exposure to topiramate with increased risk of oral clefts.
Previous studies have suggested a link between opioid exposure during pregnancy and increased risk of certain major malformations, including neural tube defects. A recent study from Bateman and colleagues assesses the risk of major malformation [...]
Clinical Update 2020:Â Lamotrigine (Lamictal) and Pregnancy Maintenance treatment with a mood stabilizer during pregnancy can significantly reduce the risk of relapse in women with bipolar disorder; however, many of the mood stabilizers commonly [...]
The anticonvulsant lamotrigine (Lamictal) is being used with increasing regularity for the treatment of women with bipolar disorder. Â Back in 2006, we reported on preliminary data indicating an increased risk of oral clefts among infants [...]
Topiramate (TPM, marketed as Topamax) is an antiepileptic drug which is also used for migraine prophylaxis, weight loss, and, less commonly, as a mood stabilizer. Over the last few years we have seen several studies suggesting an increased risk of oral clefts in infants exposed to topiramate during the first trimester of pregnancy. You can read more about those studies here:
Earlier this year we reported on a possible association between first trimester exposure to topiramate (Topamax) and increased risk of cleft lip and palate. In a recent study published by the American Journal of Obstetrics and Gynecology, researches drew upon data from two birth defect databases to further delineate the risks associated with topiramate exposure.
